Alpha Cognition Inc. (ACOG) SEC filings

ACOGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/3066% above fair value

$8.30−0.26 (-3.04%)

Close on Nov 13, 2026Market cap $180.76MP/E –Yield –

SEC filings

39 of Alpha Cognition's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 5, 2026	Nov 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Jun 16, 2026	Jun 23, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 14, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 16, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 15, 2026	Apr 20, 2026	SEC EDGAR
Current report	8-K	Apr 10, 2026	Apr 14, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 31, 2026	SEC EDGAR
Current report	8-K	Mar 27, 2026	Mar 27, 2026	SEC EDGAR
Current report	8-K	Mar 25, 2026	Mar 26, 2026	SEC EDGAR
Current report	8-K	Feb 18, 2026	Feb 23, 2026	SEC EDGAR
Current report	8-K	Jan 9, 2026	Jan 15, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Oct 10, 2025	Oct 14, 2025	SEC EDGAR
Current report	8-K	Sep 30, 2025	Oct 2, 2025	SEC EDGAR
Current report	8-K	Aug 22, 2025	Aug 22, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Jun 19, 2025	Jun 23, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 15, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 19, 2025	Apr 30, 2025	SEC EDGAR
Current report	8-K	Apr 7, 2025	Apr 10, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 31, 2025	SEC EDGAR
Current report	8-K	Feb 18, 2025	Feb 27, 2025	SEC EDGAR
Current report	8-K	Dec 16, 2024	Dec 20, 2024	SEC EDGAR
Current report	8-K	Nov 12, 2024	Nov 18, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 14, 2024	SEC EDGAR
Current report	8-K	Oct 30, 2024	Nov 5, 2024	SEC EDGAR
Current report	8-K	Oct 21, 2024	Oct 24, 2024	SEC EDGAR
Current report	8-K	Oct 8, 2024	Oct 9, 2024	SEC EDGAR
Current report	8-K	Sep 27, 2024	Oct 3, 2024	SEC EDGAR
Current report	8-K	Sep 24, 2024	Sep 25, 2024	SEC EDGAR
Current report	8-K	Aug 28, 2024	Aug 28, 2024	SEC EDGAR
Current report	8-K	Aug 27, 2024	Aug 27, 2024	SEC EDGAR
Current report	8-K	Aug 12, 2024	Aug 13, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 12, 2024	SEC EDGAR
Current report	8-K	Aug 6, 2024	Aug 9, 2024	SEC EDGAR
Current report	8-K	Jul 29, 2024	Jul 29, 2024	SEC EDGAR
Current report	8-K	Jun 10, 2024	Jun 14, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Alpha Cognition's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Nov 14, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ACOG.

Compare: ACOG vs LENZ · ACOG vs VYGR · ACOG vs XFOR · ACOG vs SCLX · ACOG vs LCTX

Gross margin92.9% · median 114.9%

Operating margin-146.9% · median -631.7%

Net margin-144.6% · median -586.7%

Company	Revenue	Growth
SCLX	$31.61M	-28.5%
VYGR	$25.11M	-19.8%
LENZ	$21.48M	+329.5%
ACOG	$20.20M	–
LCTX	$10.84M	+0.2%
XFOR	$9.90M	+73.7%

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 72
Held by institutions: 48.7%
Auditor: CBIZ CPAs P.C.
SEC CIK: 1655923

Advertisement
300 × 250

See a number that looks wrong?